# Incyte **Source:** https://geo.sig.ai/brands/incyte **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** incyte.com **Last Updated:** 2026-04-14 ## Summary Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer. ## Company Overview Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles. Incyte's oncology and inflammation biopharmaceutical model creates competitive advantages through the regulatory exclusivity and clinical depth of the JAK inhibitor franchise in hematology: ruxolitinib's decade-plus of post-marketing data across myelofibrosis, polycythemia vera, acute GVHD, and chronic GVHD creates a clinical database that competitor JAK inhibitors (fedratinib from Bristol Myers Squibb, pacritinib from CTI BioPharma) cannot replicate without years of comparative clinical experience — giving oncologists a comfort level with ruxolitinib's safety profile in fragile hematology patients that is difficult to unseat. The Opzelura dermatology franchise (topical ruxolitinib cream — the only FDA-approved topical JAK inhibitor for atopic dermatitis and the first approved treatment for non-segmental vitiligo) creates a second revenue pillar beyond hematology, as dermatologists adopt the cream for patients with moderate-to-severe atopic dermatitis who failed topical steroids and non-steroidal topical agents. The Novartis royalty stream (approximately $700-800 million annually from Novartis's international Jakavi sales) provides high-margin income that diversifies Incyte's revenue beyond US Jakafi product sales. In 2025, Incyte competes in hematology/oncology and dermatology JAK inhibitor therapeutics against Bristol Myers Squibb (NYSE: BMY, Inrebic/fedratinib for myelofibrosis), Pfizer (NYSE: PFE, Xeljanz/tofacitinib for rheumatoid arthritis and inflammatory diseases), and Eli Lilly (NYSE: LLY, Olumiant/baricitinib for rheumatoid arthritis and atopic dermatitis) for JAK inhibitor prescribing in myelofibrosis, polycythemia vera, atopic dermatitis, and emerging inflammatory indications. The Jakafi (ruxolitinib) loss of exclusivity timeline — US patents protecting ruxolitinib expire in 2028, triggering generic competition — creates urgency for Incyte to grow Opzelura dermatology revenues, axatilimab GVHD revenues, and pipeline product launches before generic ruxolitinib enters the myelofibrosis market. Opzelura's atopic dermatitis market penetration (competing with AbbVie's Rinvoq oral upadacitinib and Pfizer's Cibinqo oral abrocitinib — both oral JAK inhibitors with broader efficacy but more systemic side effects than topical ruxolitinib) positions Incyte's topical therapy for patients and physicians preferring local anti-inflammatory treatment over systemic JAK inhibition. The 2025 strategy focuses on axatilimab chronic GVHD launch ramp (Niktimvo — first CSF-1R inhibitor approved for cGVHD), Opzelura non-segmental vitiligo DTC patient awareness campaigns, and pipeline progression for povorcitinib in dermatology indications. ## Frequently Asked Questions ### What does Incyte Corporation do? Incyte Corporation is a global biopharmaceutical company that discovers, develops, and commercializes innovative medicines for serious unmet medical needs. The company focuses on three main therapeutic areas: oncology (including blood cancers), inflammation and autoimmunity (including dermatology), and hematology. Incyte is known for pioneering JAK inhibitor therapies, with flagship products Jakafi and Opzelura treating multiple conditions including myelofibrosis, polycythemia vera, graft-versus-host disease, atopic dermatitis, and vitiligo. ### When was Incyte founded and where is it headquartered? Incyte was founded in April 1991 in Palo Alto, California, originally as Incyte Pharmaceuticals. The company later relocated its headquarters to Wilmington, Delaware in 2002 when it pivoted from genomics services to drug development. Today, Incyte operates as a global organization with over 2,600 employees and maintains manufacturing and R&D facilities across North America, Europe, and Asia. ### Who are Incyte's main competitors? Incyte competes with major biopharmaceutical companies in the JAK inhibitor, oncology, and dermatology spaces. Key competitors include Eli Lilly (Olumiant), Pfizer (Xeljanz), AbbVie (Rinvoq) in the JAK inhibitor market; Bristol Myers Squibb, Novartis, and Gilead Sciences in oncology; and Pfizer, AbbVie, and specialty dermatology companies in the dermatology market. Incyte differentiates through its first-in-class innovations and expertise in rare hematologic diseases. ### What is Incyte's financial performance in 2024? Incyte reported strong financial performance in 2024 with total revenue of $4.24 billion, representing 14.76% year-over-year growth. Jakafi generated $2.8 billion in revenue (8% growth), while Opzelura achieved $508 million in revenue with impressive 50% year-over-year growth. The company has a market capitalization of approximately $13.3 billion and continues to invest heavily in R&D to advance its robust pipeline across oncology, inflammation, and autoimmunity. ### What makes Incyte different from other pharmaceutical companies? Incyte distinguishes itself through pioneering work in JAK inhibitor therapeutics, having developed the first FDA-approved JAK inhibitor (Jakafi) in 2011. The company focuses on serious diseases with high unmet medical needs, particularly rare blood cancers and autoimmune conditions. Incyte's strength lies in its deep scientific expertise with over 1,000 world-class scientists, strong clinical development capabilities, and ability to identify and develop first-in-class medicines. The company has been recognized as a top-five biotech employer by Science Magazine for seven consecutive years. ### What are Incyte's recent product launches and pipeline? Incyte launched Niktimvo for chronic graft-versus-host disease in 2024 and expects four new product launches in 2025: pediatric formulation of ruxolitinib cream for atopic dermatitis, tafasitamab for relapsed/refractory follicular lymphoma, and retifanlimab for squamous cell anal carcinoma. The pipeline includes late-stage programs in BET inhibitors for post-Jakafi myelofibrosis patients, novel oncology therapies (KRASG12Di), and continued expansion of the dermatology franchise. ### Who leads Incyte Corporation? Bill Meury serves as President and CEO of Incyte, having been appointed in June 2025. He succeeded Hervé Hoppenot, who retired after 11 years of transformative leadership. The executive team includes Dr. Pablo J. Cagnoni as President and Head of R&D, Lee Heeson as EVP and Head of Incyte International, and Matteo Trotta as EVP and General Manager of U.S. Dermatology. Julian Baker serves as Chairman of the Board of Directors. ### How many employees does Incyte have? Incyte employs over 2,600 professionals globally, including more than 1,000 world-class scientists dedicated to research and development. The company has grown significantly from 588 employees in 2014, reflecting its transformation into a global biopharmaceutical leader. Incyte operates manufacturing and R&D facilities across North America, Europe, and Asia, with its main headquarters in Wilmington, Delaware. ### What is Incyte's company culture like? Incyte's culture is rooted in the mission 'Solve On,' emphasizing relentless pursuit of medical advances for patients with unmet needs. The company values integrity, patient focus, scientific excellence, and collaboration. For the seventh consecutive year, Incyte was named a top-five biotech and pharma employer by Science Magazine in 2024. The company also ranked among Newsweek's Global Top 100 Most Loved Workplaces and received a 5-star rating for diversity, demonstrating its commitment to creating an inclusive, award-winning workplace. ### How can I contact Incyte? Incyte Corporation is headquartered at 1801 Augustine Cut-Off, Wilmington, Delaware 19803, USA. You can visit their official website at www.incyte.com for comprehensive information about products, pipeline, investor relations, and career opportunities. The company also maintains a presence on professional networks like LinkedIn and provides contact information for media inquiries, investor relations, and medical information through their website. ### Is Incyte hiring and what are career opportunities? Yes, Incyte actively recruits top talent across various functions including research and development, clinical operations, commercial, manufacturing, and corporate functions. As a rapidly growing company with four new product launches expected in 2025 and an expanding pipeline, Incyte offers diverse career opportunities. The company is known for its award-winning culture, competitive benefits, professional development programs, and employee equity ownership. Career information is available on their website at incyte.com/careers. ### What are Incyte's recent major acquisitions? Incyte has pursued strategic acquisitions to strengthen its pipeline and commercial portfolio. Major recent acquisitions include: Escient Pharmaceuticals for $750 million in May 2024, adding clinical-stage oncology assets; exclusive global rights to tafasitamab (MONJUVI) in February 2024; and Villaris Therapeutics for approximately $1.4 billion in 2022, adding vitiligo and autoimmune assets. These acquisitions complement Incyte's organic R&D efforts and demonstrate commitment to building a diversified portfolio in high-value therapeutic areas. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*